Why One Missing Report Can Change the Picture
When a team of specialists reviews your case, they do more than read your diagnosis. They piece together a complete picture of your tumor by looking at every document, scan, and test result you have. If even one key piece is missing, that picture becomes incomplete.
Glioblastoma and high-grade gliomas are not the same in every patient. Two patients with the same diagnosis can have tumors that act very differently at the molecular level. Your medical records contain information that doctors need to understand what makes your tumor unique. This includes your pathology report and all your MRI scans.
This checklist covers every report and scan you should gather before requesting an expert review. It also explains why each one matters and how to find it, no matter where you live.
What a Tumor Intelligence Review Actually Involves
An expert tumor review is different from a standard second opinion. It is a detailed analysis of your tumor's biology that looks at genetic testing, RNA analysis, and molecular tests alongside your diagnostic reports.
The goal is to find weak points in your tumor, ways it might resist treatment, and molecular features that a standard pathology report might not show. These findings help you have better conversations with your doctors about treatment choices, clinical trials, and personalized plans.
Research from the NIH National Library of Medicine shows that combining pathology findings with genetic testing has improved diagnosis and treatment planning for glioma patients. For the best results, the reviewing team needs a complete set of your medical records before they start.
Understanding Why Your Tumor's Biology Matters More Than Its Name
Most patients receive a diagnosis that sounds final: glioblastoma, IDH-wildtype, grade 4. That label describes a category, not your tumor's complete profile. Individual tumors within that category vary greatly in their genetic changes, gene patterns, and how they respond to different treatments.
Key molecular markers like MGMT promoter methylation, EGFR amplification, TERT promoter mutation, and PTEN loss tell different stories about how your specific tumor may behave. The American Brain Tumor Association recommends that newly diagnosed patients learn about their tumor's molecular details early after diagnosis.
When an expert team reviews a case, they look for the full molecular picture. This includes not just the markers tested at first diagnosis, but the patterns that show up when multiple data layers are analyzed together. That analysis needs a complete set of records.
For a detailed explanation of what these markers mean, see our guide on interpreting your glioblastoma molecular report.
What Reports Should You Gather Before Seeking an Expert Review?
The following documents are the foundation of a thorough tumor review. Gather as many as you can. If some are missing, note that when you submit. The team can work with what you have and advise on tests that might fill in gaps.
Pathology Report
This is the formal diagnosis document from your biopsy or surgery. It states the tumor type, grade, and any staining results. The pathology report is the starting point for all further analysis. Request it from the hospital or pathology department that did the analysis. In most countries, patients have a legal right to a copy of their pathology records.
Histopathology Report
Some institutions provide a separate histopathology report describing what the tumor tissue looks like under the microscope. This includes cell density, mitotic activity, blood vessel growth, and dead tissue. These details complement molecular data and help explain biological findings in the context of the tumor's physical structure.
MRI Brain Reports and Imaging Files
Every MRI scan before and after surgery matters. This includes scans before surgery, right after surgery, and all follow-up scans since treatment started. Expert review of MRI sequences like T1 with contrast, T2, FLAIR, and diffusion-weighted imaging provides information about tumor location, how much was removed, growth patterns, and how the tumor has changed over time.
When possible, request both the written radiology report and the actual imaging files in DICOM format on disc or by digital transfer. Written reports summarize one radiologist's findings, but raw images may show details that a brain tumor specialist reads differently. The National Brain Tumor Society identifies MRI scans and radiology reports as core materials for any specialist review.
Surgical Notes and Operative Report
The operative report documents what was found and done during surgery. It describes the surgical approach, how much tumor was removed (all of it, most of it, or just a biopsy), findings during surgery, and any special techniques used. How much tumor was removed directly affects how an expert team interprets what remains and what comes next. The hospital's surgical department has this document.
Molecular Testing Results
This is often the most information-rich document in your file and the one patients are least likely to have. Molecular testing results may include any of the following:
- MGMT promoter methylation status
- IDH1 and IDH2 mutation status
- TERT promoter mutation status
- EGFR amplification or EGFRvIII mutation status
- PTEN loss or mutation
- Chromosome 7 gain and chromosome 10 loss
- 1p/19q co-deletion status (especially relevant in oligodendroglioma)
- Next-generation sequencing (NGS) panel results
- Tumor mutational burden (TMB)
- Any FISH, PCR, or methylation array data
Not all hospitals do comprehensive molecular testing. Many test only MGMT methylation and IDH status at first diagnosis. If your results are limited, note that. Advanced analysis may address gaps through whole exome sequencing or RNA sequencing of tumor tissue saved from your surgery.
To understand which tests might be most relevant to your case, see our overview of what molecular tests a newly diagnosed glioblastoma actually needs.
Radiation Treatment Records
If you have completed or are receiving radiation therapy, request the radiation oncologist's treatment summary. This should describe the total dose given, the schedule, the treatment area, and any safety limits applied to nearby structures. Prior radiation affects what future treatments are possible and how imaging should be interpreted, especially when telling treatment changes from true tumor growth on follow-up MRI scans.
Current Treatment Plan
A written summary of your current treatment plan — including chemotherapy drugs, dosing schedule, and any changes made — helps the expert team understand where you are in your treatment and what has already been tried. This is usually in letters from your oncologist. Request copies of any letters sent to your family doctor or primary care physician, as these typically contain useful summaries of your current status.
Previous Treatment History
For patients with recurrence, a detailed history of all prior treatments is essential. This includes chemotherapy drugs, radiation courses, clinical trials, and surgical procedures. Treatment history shows patterns of response and resistance that are critical to finding the next best options. The molecular makeup of a recurrent tumor can be different from what was found at first diagnosis, and this history provides the context for understanding those changes.
Performance Status and Clinical Assessment Notes
Your oncologist's clinical notes typically include performance status scores like KPS or ECOG and documentation of neurological function and symptoms. These help explain biological findings within your current clinical situation and make sure that expert analysis fits your real day-to-day functioning.
Liquid Biopsy or CSF Analysis Results
If you have had a cerebrospinal fluid (CSF) analysis or a blood test for circulating tumor DNA (ctDNA), include these results. Research published in PMC (NIH) shows that CSF-based ctDNA analysis can find key mutations in glioblastoma like IDH, TERT, and EGFR changes using digital PCR and next-generation sequencing. CSF detection rates are much higher than blood plasma rates because of the blood-brain barrier. When available, liquid biopsy data adds a current molecular layer that complements what was found at surgery.
What Happens When Reports Are Incomplete
Many families arrive to seek expert review with partial records. This is common. Medical records come from different departments, different hospitals, and different times of treatment, and gathering them takes effort that patients and caregivers are rarely ready for at diagnosis.
A partial set of records does not stop a review from happening. Expert teams work with what you have and can identify what additional tests, such as advanced sequencing of tumor tissue samples saved after surgery, may fill critical gaps. The more complete your records, the deeper and more precise the analysis can be.
If you are unsure which documents you have or need, request your complete medical records from every hospital involved in your care. In the United Kingdom, the United States, Australia, Canada, Germany, France, and most of Europe, patients have a legal right to get their health information. In the UAE and some other regions, requests usually go through your doctor or hospital patient office.
How International Patients Can Submit Their Reports Remotely
Location is not a barrier to expert tumor review. Patients and caregivers worldwide access expert analysis without traveling. Pathology reports are reviewed digitally. MRI scans can be sent as DICOM files through secure digital transfer. Molecular test results are interpreted by the expert team regardless of where the original testing was done.
Initial consultations happen online. Follow-up discussion of findings happens virtually. The expertise comes to you. Dana-Farber Cancer Institute recognizes multidisciplinary specialist review, including remote consultation, as an important part of thorough glioblastoma care.
Understanding your tumor's biology may help you have better conversations with your doctors, whether you live in the same city as the reviewing team or on a different continent. For more on how remote analysis and virtual consultation work across borders, see our article on seeking a glioblastoma second opinion abroad.
Common Mistakes Families Make Before Seeking Expert Review
Several patterns consistently delay or limit the depth of expert review. Knowing them in advance can save time.
- Submitting only a diagnosis summary, not the full pathology report. Summaries leave out tissue information, staining patterns, and edge assessments that may matter for molecular interpretation.
- Providing written MRI reports without the imaging files. Written reports show one radiologist's interpretation. The raw DICOM images may show information a brain tumor specialist reads differently.
- Not requesting molecular testing results separately. These are usually held by the pathology department and are not automatically included in clinical notes. You must specifically request them.
- Assuming standard testing was comprehensive. Many hospitals test only MGMT methylation and IDH status at first diagnosis. Markers like EGFR amplification, PTEN loss, and broader genetic changes may not have been assessed.
- Waiting too long after recurrence to seek review. At recurrence, the tumor's molecular makeup may differ from the first diagnosis. Updated molecular data is more useful than relying only on older results.
- Omitting radiation records from your package. These are frequently forgotten, yet they are essential for correctly interpreting post-treatment MRI changes and planning future treatment options.
Next Steps: Requesting Your Tumor Intelligence Review
Every glioblastoma is biologically unique. A detailed review of pathology reports, molecular testing results, and imaging may reveal insights worth exploring with your doctors.
Many families seek this additional clarity before making major treatment decisions, especially at key points like the end of initial chemoradiation, considering treatment changes, or dealing with recurrence. A tumor review works alongside your local oncology team, not instead of it. The analysis provides a deeper biological assessment of your specific case that your doctors can use in shared decision-making.
International patients often start with a virtual consultation and report review. The process is straightforward: gather the documents listed in this article, upload or transfer them securely, and request an expert assessment. If you have collected your pathology reports, MRI scans, surgical notes, and molecular testing results, you have what you need to take the next step. Precision oncology analysis starts with the data you already have.
When to Talk to Your Doctor
Before gathering or submitting reports for expert review, let your treating oncologist know you are seeking additional expert input. Most doctors welcome this, and sharing the expert review findings with your care team is important. The analysis is meant to inform shared decision-making, not to bypass your existing doctors.
If you are unsure which documents to request, ask your oncologist's office or nurse coordinator for help gathering the relevant records. This is a standard part of care coordination and should not require complex work on your part.
This article is for general information and is not a substitute for medical advice. Always talk to your oncologist or care team about your specific situation.